ARCT · Arcturus Therapeutics Holdings Inc. Common Stock
View on chartInsiders & Stakes
| Payne Joseph E President and CEO | ▲ Buy | Open Market | 1,480,097 Shares held | 11/23/2022 | View profile |
| Pad Chivukula Chief Scientific Officer & COO | ▼ Sell | Open Market | 435,334 Shares held | 10/15/2024 | View profile |
| Andy Sassine Chief Financial Officer | ▲ Buy | Open Market | 221,764 Shares held | 8/15/2025 | View profile |
| Peter C. Farrell Director | ▲ Buy | Option Exercise | 55,741 Shares held | 6/14/2024 | View profile |
| James F. Barlow Director | ▲ Buy | Option Exercise | 13,131 Shares held | 6/14/2024 | View profile |
| Jing L. Marantz CHIEF MEDICAL OFFICER | ▲ Buy | Option Exercise | 3,131 Shares held | 6/14/2024 | View profile |
| Edward W. Holmes Director | ▲ Buy | Option Exercise | 3,131 Shares held | 6/14/2024 | View profile |
| John Markels Director | ▲ Buy | Option Exercise | 3,131 Shares held | 6/14/2024 | View profile |
| Magda Marquet Director | ▲ Buy | Option Exercise | 3,131 Shares held | 6/14/2024 | View profile |
| Kummerfeld Keith C See Remarks | ▼ Sell | Open Market | 950 Shares held | 7/14/2023 | View profile |
Transaction History
| Andy Sassine | ▲ Buy | Open Market | 1,238 | $20K | 8/15/2025 |
| Pad Chivukula | ▼ Sell | Open Market | 12,000 | $249K | 10/15/2024 |
| Jing L. Marantz | ▲ Buy | Option Exercise | 3,131 | $0 | 6/14/2024 |
| Edward W. Holmes | ▲ Buy | Option Exercise | 3,131 | $0 | 6/14/2024 |
| John Markels | ▲ Buy | Option Exercise | 3,131 | $0 | 6/14/2024 |
| Magda Marquet | ▲ Buy | Option Exercise | 3,131 | $0 | 6/14/2024 |
| James F. Barlow | ▲ Buy | Option Exercise | 3,131 | $0 | 6/14/2024 |
| Peter C. Farrell | ▲ Buy | Option Exercise | 3,131 | $0 | 6/14/2024 |
| Andy Sassine | ▼ Sell | Open Market | 50,000 | $1.6M | 6/12/2024 |
| Pad Chivukula | ▼ Sell | Open Market | 114 | $5K | 6/5/2024 |
| Pad Chivukula | ▼ Sell | Open Market | 26,000 | $1.0M | 6/3/2024 |
| Pad Chivukula | ▼ Sell | Open Market | 17,435 | $611K | 3/25/2024 |
| Pad Chivukula | ▼ Sell | Open Market | 8,565 | $300K | 3/19/2024 |
| Pad Chivukula | ▼ Sell | Open Market | 5,000 | $94K | 11/1/2023 |
| Pad Chivukula | ▼ Sell | Open Market | 5,000 | $128K | 10/2/2023 |
| Pad Chivukula | ▼ Sell | Open Market | 5,000 | $157K | 9/1/2023 |
| Andy Sassine | ▲ Buy | Grant | 1,223 | $21K | 8/15/2023 |
| Pad Chivukula | ▼ Sell | Open Market | 5,000 | $175K | 8/1/2023 |
| Pad Chivukula | ▼ Sell | Open Market | 25,000 | $875K | 7/14/2023 |
| Kummerfeld Keith C | ▲ Buy | Option Exercise | 4,500 | $41K | 7/14/2023 |
| Kummerfeld Keith C | ▲ Buy | Option Exercise | 1,437 | $7K | 7/14/2023 |
| Kummerfeld Keith C | ▲ Buy | Option Exercise | 1,031 | $15K | 7/14/2023 |
| Kummerfeld Keith C | ▼ Sell | Open Market | 6,968 | $244K | 7/14/2023 |
| Pad Chivukula | ▼ Sell | Open Market | 5,000 | $144K | 7/3/2023 |
| Pad Chivukula | ▼ Sell | Open Market | 5,000 | $136K | 6/1/2023 |
| Pad Chivukula | ▼ Sell | Open Market | 7,925 | $240K | 5/11/2023 |
| Pad Chivukula | ▼ Sell | Open Market | 17,075 | $512K | 5/10/2023 |
| Pad Chivukula | ▼ Sell | Open Market | 5,000 | $130K | 5/1/2023 |
| Kummerfeld Keith C | ▲ Buy | Option Exercise | 1,031 | $15K | 4/18/2023 |
| Kummerfeld Keith C | ▲ Buy | Option Exercise | 4,500 | $41K | 4/18/2023 |
| Kummerfeld Keith C | ▲ Buy | Option Exercise | 1,437 | $7K | 4/18/2023 |
| Kummerfeld Keith C | ▼ Sell | Open Market | 6,968 | $196K | 4/18/2023 |
| Pad Chivukula | ▼ Sell | Open Market | 5,000 | $127K | 4/3/2023 |
| Pad Chivukula | ▼ Sell | Open Market | 5,000 | $80K | 3/6/2023 |
| Magda Marquet | ▲ Buy | Open Market | 2,222 | $40K | 12/15/2022 |
| Payne Joseph E | ▲ Buy | Open Market | 5,000 | $83K | 11/23/2022 |
| Andy Sassine | ▲ Buy | Grant | 1,068 | $20K | 8/15/2022 |
| Pad Chivukula | ▼ Sell | Open Market | 8,100 | $324K | 1/4/2022 |
| Pad Chivukula | ▼ Sell | Open Market | 3,633 | $145K | 12/16/2021 |
| Pad Chivukula | ▼ Sell | Open Market | 6,367 | $255K | 12/8/2021 |
| Pad Chivukula | ▼ Sell | Open Market | 10,000 | $444K | 11/1/2021 |
| Pad Chivukula | ▼ Sell | Open Market | 10,000 | $444K | 10/1/2021 |
| Pad Chivukula | ▼ Sell | Open Market | 10,000 | $559K | 9/1/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Arcturus Shares Rise on Phase II Data and Analyst Upgrades
Arcturus Therapeutics reported positive Phase II data for ARCT-810 and introduced a new over-the-counter therapy platform. These updates coincided with Citigroup upgrading the stock to Buy and raising its price target to $20. The company also discussed progress in its mRNA liver therapeutics platform, contributing to the recent share price movement.
Arcturus Shares Rise on Phase II Data and Analyst Upgrades. Arcturus Therapeutics reported positive Phase II data for ARCT-810 and introduced a new over-the-counter therapy platform. These updates coincided with Citigroup upgrading the stock to Buy and raising its price target to $20. The company also discussed progress in its mRNA liver therapeutics platform, contributing to the recent share price movement.